Biomolecular condensates, membrane-less entities arising
from liquid–liquid
phase separation, hold dichotomous roles in health and disease. Alongside
their physiological functions, these condensates can transition to
a solid phase, producing amyloid-like structures implicated in degenerative
diseases and cancer. This review thoroughly examines the dual nature
of biomolecular condensates, spotlighting their role in cancer, particularly
concerning the p53 tumor suppressor. Given that over half of the malignant
tumors possess mutations in the TP53 gene, this topic carries profound
implications for future cancer treatment strategies. Notably, p53
not only misfolds but also forms biomolecular condensates and aggregates
analogous to other protein-based amyloids, thus significantly influencing
cancer progression through loss-of-function, negative dominance, and
gain-of-function pathways. The exact molecular mechanisms underpinning
the gain-of-function in mutant p53 remain elusive. However, cofactors
like nucleic acids and glycosaminoglycans are known to be critical
players in this intersection between diseases. Importantly, we reveal
that molecules capable of inhibiting mutant p53 aggregation can curtail
tumor proliferation and migration. Hence, targeting phase transitions
to solid-like amorphous and amyloid-like states of mutant p53 offers
a promising direction for innovative cancer diagnostics and therapeutics.